DermNet provides Google Translate, a free machine translation service. Note that this may not provide an exact translation in all languages
Author: Anoma Ranaweera B.V.Sc; PhD (Clinical Biochemistry, University of Liverpool, UK), 2013.
On August 26, 2013, the U. S. Food and Drug Administration (FDA) approved brimonidine (Mirvaso®) topical gel, 0.33%* (Galderma Laboratories, Texas, USA) for the topical treatment of persistent (non-transient) facial erythema (redness) of rosacea in adults 18 years of age or older.
It is the first and only FDA-approved topical treatment specifically developed and indicated for persistent facial erythema in rosacea.
The approval of brimonidine topical gel was based on data collected from more than 550 patients enrolled in two phase 3 clinical studies, each of one-month duration. The results from both studies showed that adults who used Mirvaso demonstrated significantly greater improvement in the facial redness of rosacea than vehicle gel. In addition, a long-term study in 276 subjects who used brimonidine topical gel for up to 12-months was also conducted.
Key efficacy findings are summarised in the table and figures below.
|Success*||Study 1||Study 2|
|Mirvaso® topical gel (N=129)||Vehicle gel (N=131)||Mirvaso® topical gel (N=148)||Vehicle gel (N=145)|
*2-grade improvement on CEA and 2-grade improvement on PSA scale on day 29
Adverse reactions reported in 330 individuals treated with topical brimonidine gel applied once daily for 29 days are summarised in the table below.
|Mirvaso® topical gel (N=330) No. patients (%)||Vehicle gel (N=331) No. patients (%)|
|Erythema||12 (4%)||3 (1%)|
|Skin burning sensation||5 (2%)||2 (1%)|
|Dermatitis||3 (1%)||1 (<1%)|
|Paraesthesia (tingling/prickly)||2 (1%)||1 (<1%)|
|Acne||2 (1%)||1 (<1%)|
|Vision blurred||2 (1%)||0|
|Nasal congestion||2 (1%)||0|
National Rosacea Society
See the DermNet NZ bookstore
The New Zealand approved datasheet is the official source of information for this prescription medicine, including approved uses and risk information. Check the New Zealand datasheet on the Medsafe website.
© 2019 DermNet New Zealand Trust.
DermNet NZ does not provide an online consultation service. If you have any concerns with your skin or its treatment, see a dermatologist for advice.